MONTREAL, April 4 /CNW Telbec/ - OrbiMed, a leading investment management firm focused on the healthcare
sector, announces the purchase by way of a private placement of
40,225,261 units ("Units") of MethylGene Inc. ("MethylGene"), a Montreal based clinical-stage biopharmaceutical company that
develops novel therapeutics for cancer and infectious disease, at a
subscription price of $0.1243 per Unit. Each Unit consists of one
common share of MethylGene ("Common Share") and thirty one-hundredths (0.30) of a common share purchase warrant
of MethylGene ("Warrant"). Each whole Warrant will entitle the holder to acquire one additional
Common Share and is exercisable for a period of five years from the
date of issuance, at an exercise price of $0.1492 per Common Share. The
total purchase price was approximately $5,000,000 and the private
placement was successfully completed on April 4, 2011.
Upon completion of the private placement, the OrbiMed entity, OrbiMed
Private Investments IV, LP, held 40,225,261 Common Shares and
12,067,578 Warrants resulting in ownership of approximately 13%, on a
fully diluted basis, of MethylGene.
The Common Shares and Warrants were acquired for investment purposes,
and OrbiMed Private Investments IV, LP may acquire further Common
Shares and/or Warrants, or dispose of its holdings of Common Shares
and/or Warrants, as investment conditions warrant. The Common Shares
and Warrants were acquired pursuant to section 2.3 of National
Instrument 45-106 Prospectus and Registration Exemptions as OrbiMed Private Investments IV, LP satisfies the definition of an
'accredited investor' under securities legislation.
OrbiMed has its head office at 767 Third Avenue, 30th Floor, New York,
NY 10017. For further information, including a copy of the early
warning report, please contact Alex Cooper at (212) 739-6400.
SOURCE ORBIMED ADVISORS, LLC
For further information: